Figure 2.
The effect of selected RTKIs on NFAT gene transcription stimulated by 1 nM VEGF165a. VEGFR2 NFAT cells were treated with (A) cediranib, (B) pazopanib, (C) vandetanib or (D) sorafenib. Data are mean ± SEM of five separate experiments. Data are expressed as a percentage of the response to 1 nM VEGF165a in the absence of RTKIs. Each individual experiment was performed in quadruplicate.